| ID | Analyse | Domein | Recipiënt | Uitvoering | LTAT (uren (dagen)) | Accred. | LOINCeenheid (1) | LOINCeenheid (2) | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 24795 | PSA PSA (screening) | Serum |
maandag t/m vrijdag | 2 (0,1) | B | 2857-1 µg/L | – | › | ||
| 2828 | p-Tau217 | EDTA |
– | – pg/mL | – | › | ||||
| 21241 | PT coumarine+INR PT + INR, Quicktijd + International Normalised Ratio, Weefseltromboplastinetijd + International Normalised Ratio | Citraat |
1 (0,1) | – | – | – | › | |||
| 90536 | Punch biopsie | Biopsie |
– | – | – | › | ||||
| 28700 | Punctievocht macroscopie | Gewrichtsvocht |
18 (0,8) | – | – | – | › | |||
| 7050 | Purines, Pyrimidines | Urine |
1× per 3–4 weken | – | 79677-1 | – | › | |||
| 4780 | Puumala virus | Serum |
149 (6,2) | – | – | – | › | |||
| 6965 | Pyridinoline/creatinine | – | – | – | › | |||||
| 1684 | Pyruvaatkinase in RBC Pyruvaatkinase intraerythrocytair | EDTA |
459 (19,1) | – | 32552-2 U/g Hb | – | › | |||
| 5621 | Quetiapine Seroquel | Serum |
163 (6,8) | – | 26776-5 µg/L | – | › | |||
| 4718 | Rabies-serologie Hondsdolheid antistoffen | Serum |
544 (22,7) | – | – IU/ml | – | › | |||
| 28772 | RA (kwantitatief) | Gewrichtsvocht |
maandag t/m vrijdag | 14 (0,6) | – | – IU/ml | – | › | ||
| 24647 | Ratio SARS-CoV-2 S/N IgG Coronavirus 19, COVID-19, Severe Acute Respiratory Syndrome | Serum (2×) |
72 (3) | – | – | – | › | |||
| 24646 | Ratio SARS-CoV-2 S/N IgG | Serum |
maandag t/m vrijdag | n.v.t. | – | – (LogU/ml)/(COI) | – | › | ||
| 7044 | Reducerende suikers Reducerende sacchariden | Urine |
– | – | – | › | ||||
| 25069 | Renine Actieve renine concentratie, ARC, Directe renine concentratie | EDTA |
maandag t/m vrijdag | 52 (2,2) | – | 30895-7 mIU/L | 35570-1 pmol/L | › | ||
| 28129 | Respiratoire pathogenen Respiratoire micro-organismen panel, Viraal panel | DNA-wisser |
68 (2,8) | – | – | – | › | |||
| ● 21200 | Reticulocyten | EDTA |
maandag t/m zaterdag | 1 (0) | – | 4679-7 % | – | › | ||
| 23032 | Retinol bindend proteine | Serum |
– | 1836-6 g/L | – | › | ||||
| 23120 | Reumafactor IgM RF, Reumafactor, Rheumafactor | Serum |
maandag t/m vrijdag | 3 (0,1) | – | 11572-5 IU/mL | – | › | ||
| 24922 | Reverse T3 Reverse triiodothyronine, rT3 | Serum |
1× per week | 160 (6,7) | – | 3052-8 ng/dl | 14929-4 nmol/l | › | ||
| 351 | RhD-moleculair | EDTA |
166 (6,9) | – | 971351 | – | › | |||
| 57496 | Rhodium /g creatinine Rh | Urine |
250 (10,4) | – | – | – | › | |||
| 4816 | Rickettsia conorii IF IgG | Serum |
241 (10) | – | 21492-4 | – | › | |||
| 4776 | Rickettsia PCR | eSwab |
1× per 1–2 weken | – | 67726-0 | – | › | |||
| 4850 | Rickettsia typhi IF IgG | Serum |
124 (5,2) | – | 22489-9 | – | › | |||
| 71009 | Rijst f9 IgG | Serum |
2× per week, op dinsdag en vrijdag | 2 (0,1) | – | 35545-3 mgA/l | – | › | ||
| 34383 | Risico pre-eclampsie EPE | Serum |
95 (4) | – | – | – | › | |||
| 6122 | Risperidone 9-hydroxyrisperidon, 9-hydroxyrisperidone, Invega | Serum |
128 (5,3) | – | – | – | › | |||
| 69862 | Rkn.pt.fRhD genotypering | EDTA |
172 (7,2) | – | – | – | › | |||
| 23193 | Ro52/TRIM21 Anti-RO, Anti-Sjögren's syndrome A ab | Serum |
maandag t/m vrijdag | 6 (0,2) | – | 82933-3 AU/mL | – | › | ||
| 26554 | Rode bloedcellen | Urine |
maandag t/m zaterdag | 3 (0,1) | B | 798-9 /µl | – | › | ||
| 71005 | Rogge f5 IgG | Serum |
2× per week, op dinsdag en vrijdag | 108 (4,5) | – | 51933-0 mgA/l | – | › | ||
| 28302 | Rotavirus Ag Rota antigeen | Faeces |
maandag t/m vrijdag | 64 (2,6) | B | 17547-1 | 97128302 | › | ||
| 29292 | RSV antigeen | Aspiraat (nasopharynx) |
maandag t/m vrijdag | 2 (0,1) | – | – | – | › | ||
| 24574 | Rubella bevestiging | Serum |
20 (0,8) | – | – | – | › | |||
| 24547 | Rubella IgG vrouw | Serum |
maandag t/m vrijdag | 1 (0,1) | B | 8014-3 IU/mL | – | › | ||
| 24546 | Rubella IgM | Serum |
maandag t/m vrijdag | 1 (0,1) | B | 8015-0 Index | – | › | ||
| 71027 | Rundvlees f27 IgG | Serum |
2× per week, op dinsdag en vrijdag | – | – mgA/l | – | › | |||
| 57476 | Ruthenium /g creatinine | Urine |
282 (11,7) | – | – | – | › | |||
| 71315 | Ruwe berk t3 IgG | Serum |
2× per week, op dinsdag en vrijdag | 111 (4,6) | – | – mgA/l | – | › | ||
| 4942 | S100 | Serum |
tenminste 2× per week | 41 (1,7) | – | 83114-9 µg/L | – | › | ||
| 57988 | Salicylaten | Urine |
167 (6,9) | – | 4026-1 mg/dL | – | › | |||
| 55660 | Salicylzuur Acenterine, Acetylsalicylzuur, Aspirine | Serum |
bij ontvangst van het staal | 167 (6,9) | – | 3306-8 mg/dl | 14909-6 µmol/L | › | ||
| 24110 | Salmonella (Widal) Widal | Serum |
6 (0,2) | – | 98211-6 | – | › | |||
| 71061 | Sardien f61 IgG | Serum |
2× per week, op dinsdag en vrijdag | – | 63134-1 mgA/l | – | › | |||
| 24645 | SARS-CoV-2-N-IgG/IgM Coronavirus 19, COVID-19, Severe Acute Respiratory Syndrome | Serum |
maandag t/m vrijdag | 68 (2,8) | – | 97124645 COI | – | › | ||
| 24589 | SARS-CoV-2-S antistoffen Coronavirus 19, COVID-19, Severe Acute Respiratory Syndrome | Serum |
maandag t/m vrijdag | 24 (1) | – | 94505-5 U/mL | – | › | ||
| 4872 | SCC Ag SCC Ag | Serum |
2× per week, op dinsdag en vrijdag | 86 (3,6) | – | 9679-2 µg/L | – | › | ||
| 4882 | SCC Ag SCC Ag | Serum |
2× per week, op dinsdag en vrijdag | 61 (2,5) | – | 9679-2 µg/L | – | › |